Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension

Sun,Ningling; Feng,Yingqing; Gao,Pingjin; Chen,Xiaoping; Qi,Litong; Zhang,Shuyang; Dong,Yugang; Yang,Xinchun; Li,Xinli; Chen,Yundai; Liu,Lingli

doi:10.3892/etm.2017.4051

March-2017 Volume 13 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2017 Volume 13 Issue 3

Full Size Image

Article

Efficacy and tolerability of once‑daily 160 mg valsartan in Chinese patients with mild to moderate hypertension

Authors:
- Ningling Sun
- Yingqing Feng
- Pingjin Gao
- Xiaoping Chen
- Litong Qi
- Shuyang Zhang
- Yugang Dong
- Xinchun Yang
- Xinli Li
- Yundai Chen
- Lingli Liu
View Affiliations / Copyright

Affiliations: Department of Cardiology, Peking University People's Hospital, Beijing 100044, P.R. China, Department of Cardiology, Guangdong General Hospital, Guangdong Cardiovascular Institute, Guangzhou, Guangdong 510080, P.R. China, Department of Hypertension, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China, Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Cardiology, Peking University First Hospital, Beijing 100034, P.R. China, Department of Cardiology, Peking Union Medical College Hospital, Beijing 100730, P.R. China, Department of Cardiology, First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China, Department of Cardiology, Beijing Chao‑yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Cardiology, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Cardiology, Academy of Military Medical Sciences, Beijing 100850, P.R. China, Medical Affairs, Novartis Pharmaceuticals, Beijing 100004, P.R. China
Pages: 1109-1116
|
Published online on: January 17, 2017

https://doi.org/10.3892/etm.2017.4051
Expand metrics +

Abstract

The present multicentre, prospective, open‑label, single treatment arm study (Val‑Perfect) examined the efficacy and tolerability of once‑daily valsartan monotherapy (80 mg for two weeks, followed by 160 mg for eight weeks) in 195 Chinese patients with mild to moderate hypertension, using office, home, and ambulatory blood pressure (BP) monitoring. Significant mean reductions (P<0.0001) were observed in office BP from baseline to week 10, with mean sitting systolic BP (MSSBP) and mean sitting diastolic BP (MSDBP) values of 15.6±12.3 and 11.1±8.6 mmHg, respectively. The office BP control rate at week 10 was 56.9% (target MSSBP/MSDBP <130/80 mmHg for patients with type 2 diabetes or chronic kidney disease, <140/90 mmHg for others). Valsartan treatment significantly reduced mean 24‑h SBP/DBP (‑6.1/‑4.4 mmHg; both P<0.0001) and mean home‑monitored SBP/DBP (‑13.3/‑9.1 mmHg; both P<0.0001) at week 10. The incidence of adverse events (AEs) leading to discontinuation (1.5%) or drug‑related AEs (3.1%) was low, with no instances of mortality or drug‑related serious AEs. These results indicate that 160 mg valsartan is safe and effective at lowering BP in Chinese patients with mild to moderate hypertension. The significant reductions in office‑based and out‑of‑office BP measures support the clinical relevance of moderate‑dose valsartan monotherapy for effective 24‑h BP control.

View Figures

View References

1	Chiang CE and Chen CH: Hypertension in the Asia-Pacific region. J Hum Hypertens. 22:441–443. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kearney PM, Whelton M, Reynolds K, Whelton PK and He J: Worldwide prevalence of hypertension: A systematic review. J Hypertens. 22:11–19. 2004. View Article : Google Scholar : PubMed/NCBI
3	Hu DY, Liu LS, Yu JM and Yao CH: China STATUS Study Group: National survey of blood pressure control rate in Chinese hypertensive outpatients-China STATUS. Zhonghua Xin Xue Guan Bing Za Zhi. 38:230–238. 2010.(In Chinese). PubMed/NCBI
4	Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al: 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 23:3–16. 2014. View Article : Google Scholar : PubMed/NCBI
5	Verdecchia P and Angeli F: Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther. 26:460–472. 2004. View Article : Google Scholar : PubMed/NCBI
6	Markham A and Goa KL: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 54:299–311. 1997. View Article : Google Scholar : PubMed/NCBI
7	Parati G, Asmar R, Bilo G, Kandra A, Di Giovanni R and Mengden T: Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: The ValTop study. Hypertens Res. 33:986–994. 2010. View Article : Google Scholar : PubMed/NCBI
8	Pool JL, Glazer R, Chiang YT and Gatlin M: Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 13:275–281. 1999. View Article : Google Scholar : PubMed/NCBI
9	Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 363:2022–2031. 2004. View Article : Google Scholar : PubMed/NCBI
10	Study Group NAVIGATOR, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, et al: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 362:1477–1490. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ke YN, Dong YG, Ma SP, Yuan H, Ihm SH and Baek SH: ADVISE study group: Improved blood pressure control with nifedipine GITS/valsartan combination versus high-dose valsartan monotherapy in mild-to-moderate hypertensive patients from Asia: Results from the ADVISE study, a randomized trial. Cardiovasc Ther. 30:326–332. 2012. View Article : Google Scholar : PubMed/NCBI
12	Zhu D, Yang K, Sun N, Gao P, Wang R, Grosso A and Zhang Y: trial investigators: Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. Int J Cardiol. 167:2024–2030. 2013. View Article : Google Scholar : PubMed/NCBI
13	Stergiou GS, Nasothimiou E, Giovas P, Kapoyiannis A and Vazeou A: Diagnosis of hypertension in children and adolescents based on home versus ambulatory blood pressure monitoring. J Hypertens. 26:1556–1562. 2008. View Article : Google Scholar : PubMed/NCBI
14	Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, et al: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 348:2407–2415. 2003. View Article : Google Scholar : PubMed/NCBI
15	Perloff D, Sokolow M and Cowan R: The prognostic value of ambulatory blood pressures. JAMA. 249:2792–2798. 1983. View Article : Google Scholar : PubMed/NCBI
16	Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 24:793–801. 1994. View Article : Google Scholar : PubMed/NCBI
17	National Revision Committee for the Guidelines on Prevention and Control of Hypertension in China, . Guidelines On Prevention And Control Of Hypertension In China 2010. Chinese Journal of Hypertension. 19:701–741. 2011.
18	Oparil S, Dyke S, Harris F, Kief J, James D, Hester A and Fitzsimmons S: The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 18:797–810. 1996. View Article : Google Scholar : PubMed/NCBI
19	Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S and Shi Y: Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 12:861–866. 1998. View Article : Google Scholar : PubMed/NCBI
20	Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y and Mallows S: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 11:483–489. 1997. View Article : Google Scholar : PubMed/NCBI
21	Huang J, Sun NL, Hao YM, Zhu JR, Tu Y, Curt V and Zhang Y: Trial Investigators: Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens. 33:179–186. 2011. View Article : Google Scholar : PubMed/NCBI
22	Nash DT, Crikelair N and Zappe D: Achieving BP goals with valsartan and HCTZ alone and in combination: Pooled analysis of two randomized, double-blind, placebo-controlled studies. Curr Med Res Opin. 24:2617–2626. 2008. View Article : Google Scholar : PubMed/NCBI
23	Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P and Hester A: Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther. 20:1106–1114. 1998. View Article : Google Scholar : PubMed/NCBI
24	Weir MR, Levy D, Crikelair N, Rocha R, Meng X and Glazer R: Time to achieve blood-pressure goal: Influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 20:807–815. 2007. View Article : Google Scholar : PubMed/NCBI
25	Fogari R and Zoppi A: A drug safety evaluation of valsartan. Expert Opin Drug Saf. 10:295–303. 2011. View Article : Google Scholar : PubMed/NCBI